Biodexa Pharmaceticals (BDRX) — Strategic Asset Allocation Index
Biodexa Pharmaceticals (BDRX) has a Strategic Asset Allocation Index of 13.1% as of June 2023. Strategic assets (PP&E of $693.00K plus long-term investments of $-) total $693.00K, measured against net assets of $5.30 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Biodexa Pharmaceticals Strategic Asset Allocation Index (2019–2021)
This chart shows how Biodexa Pharmaceticals's Strategic Asset Allocation Index has evolved across 3 annual periods from 2019 to 2021. As of June 2023, the index stands at 13.1%, representing strategic assets of $693.00K against net assets of $5.30 Million USD. Explore how efficiently does Biodexa Pharmaceticals generate cash to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Biodexa Pharmaceticals (2019–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Biodexa Pharmaceticals from 2019 to 2021, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see BDRX stock market capitalisation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 11.0% | $1.15 Million | $1.15 Million | $- | $10.45 Million | ▲ +3.0 pp |
| 2020 | 8.1% | $542.00K | $542.00K | $- | $6.72 Million | ▼ -2.9 pp |
| 2019 | 11.0% | $2.15 Million | $2.15 Million | $- | $19.56 Million | — |